Ebola medical therapy: Difference between revisions
| Line 15: | Line 15: | ||
*Maintaining [[oxygen]] and [[blood]] levels | *Maintaining [[oxygen]] and [[blood]] levels | ||
*Treating any complicating [[infections]]. | *Treating any complicating [[infections]]. | ||
Convalescent Plasma (factors from those who have survived Ebola infection) shows promise as a treatment for the disease. [[Ribavirin]] is ineffective. [[Interferon]] is also thought to be ineffective. In monkeys, administration of an inhibitor of coagulation (rNAPc2) has shown some benefit, protecting 33% of infected animals from a usually 100% (for monkeys) lethal infection<ref name=" | Convalescent Plasma (factors from those who have survived Ebola infection) shows promise as a treatment for the disease. [[Ribavirin]] is ineffective. [[Interferon]] is also thought to be ineffective. In monkeys, administration of an inhibitor of coagulation (rNAPc2) has shown some benefit, protecting 33% of infected animals from a usually 100% (for monkeys) lethal infection<ref name="pmid14683653">{{cite journal| author=Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J et al.| title=Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. | journal=Lancet | year= 2003 | volume= 362 | issue= 9400 | pages= 1953-8 | pmid=14683653 | doi=10.1016/S0140-6736(03)15012-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14683653 }} </ref> (unfortunately this inoculation does not work on humans). In early 2006, scientists at [[USAMRIID]] announced a 75% recovery rate after infecting four [[rhesus monkey]]s with Ebola virus and administering [[Antisense therapy|antisense drugs]]. | ||
==References== | ==References== | ||
Revision as of 15:00, 18 June 2014
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola medical therapy On the Web |
|
American Roentgen Ray Society Images of Ebola medical therapy |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ebola is potentially lethal and since no approved vaccine or treatment is available. Treatment is primarily supportive and includes maintaining fluids and electrolytes homeostasis, adequate oxygen and blood levels and treating any complicating infections.[1] All patients with a confirmed or suspected viral hemorrhagic fever should be put in isolation and adequate contact precautions.[2]
Medical Therapy
Treatment is primarily supportive and includes:
- Minimizing invasive procedures
- Balancing electrolytes since patients are frequently dehydrated
- Replacing lost coagulation factors to help stop bleeding
- Maintaining oxygen and blood levels
- Treating any complicating infections.
Convalescent Plasma (factors from those who have survived Ebola infection) shows promise as a treatment for the disease. Ribavirin is ineffective. Interferon is also thought to be ineffective. In monkeys, administration of an inhibitor of coagulation (rNAPc2) has shown some benefit, protecting 33% of infected animals from a usually 100% (for monkeys) lethal infection[3] (unfortunately this inoculation does not work on humans). In early 2006, scientists at USAMRIID announced a 75% recovery rate after infecting four rhesus monkeys with Ebola virus and administering antisense drugs.
References
- ↑ "Ebola Hemorrhagic Fever Information Packet" (PDF).
- ↑ Feldmann H, Geisbert TW (2011). "Ebola haemorrhagic fever". Lancet. 377 (9768): 849–62. doi:10.1016/S0140-6736(10)60667-8. PMC 3406178. PMID 21084112.
- ↑ Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J; et al. (2003). "Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys". Lancet. 362 (9400): 1953–8. doi:10.1016/S0140-6736(03)15012-X. PMID 14683653.